Effects of Adherence to Pharmacological Treatment on the Recovery of Patients with Schizophrenia

Caqueo-Urízar, Alejandra; Urzúa, Alfonso; Mena-Chamorro, Patricio; Fuente, Josefa Bravo de la

doi:10.3390/healthcare9091230

Cited by 8 publications

(11 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epilepsy and schizophrenia are still viewed in the majority of the world as an evil spirit. Although two-thirds of patients could become seizure-free with proper care, poor adherence to proper guidelines is a major problem for effective recovery [32,33]. In an Indian study, 60% of the participants thought that illnesses were the result of luck or superstition [34].…”

Section: Of 23mentioning

confidence: 99%

Low Health Literacy (LHL): A Devious Enemy of Patient Treatment Adherence

Mohiuddin¹

2023

Preprint

View full text Add to dashboard Cite

People must have particular personality traits and social resources, also known as health literacy, in order to access, comprehend, and use information to make decisions about their health. Patients' ability to engage in complex disease management and self-care is strongly related to their level of health literacy. It can help us stay healthy by preventing illness and effectively managing existing illnesses. People with low health literacy (LHL) may find it difficult to manage their condition and prevent illness, which may lead to increased use of healthcare services. Furthermore, LHL is associated with increased hospitalizations, increased use of emergency care, decreased use of preventative services, and a worsened ability to understand labels and health messages, a worsened state of health, higher mortality, and more expensive medical care.

show abstract

Section: Of 23mentioning

confidence: 99%

Low Health Literacy (LHL): A Devious Enemy of Patient Treatment Adherence

Mohiuddin¹

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The clinical guidelines of the American Psychiatric Association indicate that pharmacotherapy is the treatment approach with the highest level of evidence in terms of effectiveness compared to other approaches (Keepers et al, 2020). However, medication adherence in persons may be interrupted by numerous factors, including symptom severity, side effects of drugs, medication attitude, insight, and support system, resulting in a non‐adherence rate of 58.2%, which is associated with high medical and social costs, affecting the progression and recovery of individuals' disease process (Caqueo‐Urízar et al, 2021; Nyanyiwa et al, 2022; Pennington & McCrone, 2018; Vega et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Effects of empowerment‐based illness management on the medication adherence and recovery of persons with schizophrenia: A systematic review and meta‐analysis

Hsieh

Liu

2023

Int J Mental Health Nurs

View full text Add to dashboard Cite

Medication adherence and recovery rates are <50% among persons with schizophrenia; therefore, this health concern needs attention. Empowerment is a vital element for behavioural change, but previous studies have presented different results and lack specific connotations about empowerment. Therefore, this study systematically reviewed and meta-analysed the effects of empowerment-based illness management on the medication adherence and recovery of persons with schizophrenia. The databases searched included the PROSPERO registration network, Cochrane Library, PubMed, Embase, CINAHL, PsycAricle, and Airiti Library. The research steps were based on PRISMA. RoB 2.0 was used for article quality evaluation, the effect size was calculated using RevMan software, and the random-effect model and standardized mean differences (SMD) were established. Eight randomized controlled trials (RCTs) involving 859 participants were used to investigate the effect of empowerment on medication adherence. The trials involved the use of effective strategies as inducing medication motivation, promoting selfmedication management, and providing support resources. A moderate effect was observed (SMD = 0.58, 95% CI 0.18-0.99). Ten RCTs involving 1473 participants were used to investigate the effect of empowerment on recovery. These trials involved the use of such effective strategies as using self-strength, connecting external forces, understanding personal needs, and overcoming self-stigma. A moderate effect was observed (SMD = 0.55, 95% CI 0.10-0.99). Empowerment in illness management can effectively promote the medication adherence and recovery of persons with schizophrenia. In the future, nurses can use self-strength care to promote medication motivation and connect internal and external forces to assist a person's medication adherence and recovery.

show abstract

“…10 A number of factors hinder recovery including cognitive dysfunction, 11 mood disorders, 12 and poor adherence to medications. 13 Lurasidone is a drug with a pharmacological profile that acts as an antagonist for dopamine D2, serotonin (5-HT)7 and 5-HT2A receptors, and as a partial agonist for 5-HT1A receptors, with minimal binding affinity for histamine H1 and muscarinic M1 receptors. 14 In 2020, lurasidone 40 mg/d to 80 mg/d was approved in Japan for the treatment of schizophrenia based on the results of a 6-week double-blind, placebo-controlled study of the treatment of schizophrenia in some countries including Japan (JEWEL study; EudraCT number: 2016-000060-42), 15 a 12-week open-label extension study (JEWEL extension study; EudraCT number: 2016-000061-23), 16 and other clinical trials conducted in the USA and Europe countries.…”

Section: Introductionmentioning

confidence: 99%

“… 10 A number of factors hinder recovery including cognitive dysfunction, 11 mood disorders, 12 and poor adherence to medications. 13 …”

Section: Introductionmentioning

confidence: 99%

Effectiveness of Lurasidone 80 mg in Patients with Schizophrenia: Results of an Open-Label, 12-Week Extension Study

Miura¹,

Watabe²,

Sakaguchi³

et al. 2022

NDT

View full text Add to dashboard Cite

To evaluate the effectiveness and safety of lurasidone 80 mg/day (versus the 40 mg/day dose) during a 12-week, open-label extension study in patients with an acute exacerbation of schizophrenia who had completed a 6-week double-blind study of lurasidone. Patients and Methods: A total of 289 adult patients with schizophrenia completed the double-blind study and enrolled in the 12-week extension study. Lurasidone was flexibly dosed at 40 or 80 mg/day. Effectiveness measures included the Positive and Negative Syndrome Scale (PANSS) subscale scores, Clinical Global Impression-Severity Scale (CGI-S), and Calgary Depression Scale for Schizophrenia (CDSS), analyzed based on last observation carried forward (LOCF-endpoint). Safety/tolerability assessments included adverse events, body weight, laboratory tests, and discontinuation due to adverse events. Results: Mean endpoint change was greater for lurasidone in modal doses of 80 mg/d (N=136) vs 40 mg/d (N=153) on the PANSS positive subscale (−3.0 vs −2.3), PANSS negative subscale (−1.9 vs −1.7), PANSS General Psychopathology subscale (−5.1 vs −3.8), the CGI-S score (−0.5 vs −0.4), and the CDSS score (−0.7 vs −0.1). Discontinuation rates due to adverse events on lurasidone modal 80 mg/d vs 40 mg/d were 4.4% vs 7.2%; and the most common adverse events in the modal 80 mg/d group were nasopharyngitis, 7.4% (vs 4.6% on modal 40 mg/d), constipation, 5.9% (vs 2.0%), and headache, 5.9% (vs 2.0%). Conclusion:In patients with acute schizophrenia treated with lurasidone 40 mg/d, increasing the dose to 80 mg/d was well tolerated, and was associated with greater improvement in PANSS subscale scores compared to continued treatment with a dose of 40 mg/d.

show abstract

Effects of Adherence to Pharmacological Treatment on the Recovery of Patients with Schizophrenia

Cited by 8 publications

References 64 publications

Low Health Literacy (LHL): A Devious Enemy of Patient Treatment Adherence

Low Health Literacy (LHL): A Devious Enemy of Patient Treatment Adherence

Effects of empowerment‐based illness management on the medication adherence and recovery of persons with schizophrenia: A systematic review and meta‐analysis

Effectiveness of Lurasidone 80 mg in Patients with Schizophrenia: Results of an Open-Label, 12-Week Extension Study

Contact Info

Product

Resources

About